Baker McKenzie: One eye open

Baker McKenzie: One eye open

‘What defines Baker McKenzie over the last few years is the sheer amount of work that has gone into financial integration. This is a massive achievement but it has come at a cost. Now, establishing the differentiator to attract the next generation is important. It isn’t going to turn into Kirkland & Ellis, but what is going to drive that entrepreneurial aspect now Bakers looks more like other firms?’ So speaks one commentator of the quandary facing Baker McKenzie, a sentiment reprising a prevailing theme of our 2017 deep dive into the firm, ‘Waking the Giant’, which found a firm struggling to maintain its unique international selling point amid escalating globalisation of Big Law.

Then, the firm had just embarked on a new and ambitious phase, with the respected veteran intellectual property (IP) partner Paul Rawlinson instated as its first British chair in October 2016. The mandate? To implement the firm’s 2020 strategy, which focused on integrating Bakers across three profit pools, increasing profitability and growing the firm’s transactional practices in London, New York and China. Continue reading “Baker McKenzie: One eye open”

‘You’d be a brave innovator to ignore the UK’ – why patent work is booming in the post-Brexit UK life sciences market

‘You’d be a brave innovator to ignore the UK’ – why patent work is booming in the post-Brexit UK life sciences market

Buzz about blockbuster drug developments, expiring patents and the launch of the European Union’s Unified Patent Court – 2023 certainly kept the life sciences sector on its toes.

Against a backdrop of several of the world’s best-selling drugs nearing their patent expiration dates and the market getting to grips with the implications of the long-awaited EU patent court, leading practitioners at UK law firms provide their perspective on the evolving world of IP and patent litigation in the life sciences sector – and what these changes mean for corporates and their in-house legal teams.
Continue reading “‘You’d be a brave innovator to ignore the UK’ – why patent work is booming in the post-Brexit UK life sciences market”

Taking back control – the post-pandemic landscape for life sciences regulation

Taking back control – the post-pandemic landscape for life sciences regulation

After years of delays caused by geopolitical instability and the Covid-19 pandemic, the new regulatory landscape for the life sciences industry is beginning to take shape in both the UK and the EU.

As the UK pushes ahead with its post-Brexit journey of divergence, establishing itself as an innovation-friendly environment in the global life sciences market has become of paramount importance. In contrast, the EU’s attempts to draft comprehensive laws on AI have attracted criticism from the medical devices industry, prompting overburdened innovators to turn to more investment-friendly locations. Continue reading “Taking back control – the post-pandemic landscape for life sciences regulation”

Life Sciences perspectives: Grant Castle

Life Sciences perspectives: Grant Castle

Why did you decide to specialise in life sciences?

I have a science background – a PhD in organic chemistry – and worked for a short time as a medicinal chemist for Glaxo. I also had an interest in the humanities at school, so law had always seemed to be an option, and life sciences law made sense. I had assumed that I would go into IP/patents, but was lucky enough to meet a life sciences regulatory lawyer from Covington and spent some time there before my training contract. I came back to Covington on qualification and I am still here 25 years later. I clearly made the right choice. Continue reading “Life Sciences perspectives: Grant Castle”

Rising stars: Zina Chatzidimitriadou – ‘It is the one legal area that affects every single one of us and is, above all, human-centred’

Rising stars: Zina Chatzidimitriadou – ‘It is the one legal area that affects every single one of us and is, above all, human-centred’

Zina Chatzidimitriadou, senior managing associate at Sidley, on why she picked a career in life sciences law

Why did you decide to specialise in life sciences law?

In 2009, in my previous life as a molecular biologist at the Cancer Research UK institute, I experienced the multiple issues and complexities facing researchers and people involved in the development of life-saving treatments and methods. Life sciences emerged as the natural field of law for me and, while I am biased, I believe it is the most exciting field of law. Continue reading “Rising stars: Zina Chatzidimitriadou – ‘It is the one legal area that affects every single one of us and is, above all, human-centred’”

Rising stars: Jaspreet Takhar – ‘EU regulators are preparing an avalanche of new laws that are going to have a monumental impact on pharma and medtech’

Rising stars: Jaspreet Takhar – ‘EU regulators are preparing an avalanche of new laws that are going to have a monumental impact on pharma and medtech’

Baker McKenzie’s Jaspreet Takhar on the future of digital health solutions

What made you decide to specialise in life sciences law?

I specialise in advising on digital health solutions – that means advising on the regulation of health data, digital health solutions (including AI solutions, software and medical devices), as well as contracting in this space. I genuinely find the digital health space as exciting as it gets! The legal landscape is changing at breakneck speed, and I spend a few minutes every morning scanning for new regulations, new announcements and new guidance. Hot topics for legal developments include the regulation of AI, the European Health Data Space, and local laws on medical confidentiality. Continue reading “Rising stars: Jaspreet Takhar – ‘EU regulators are preparing an avalanche of new laws that are going to have a monumental impact on pharma and medtech’”

Rising stars: Dr Chris Boyle – ‘AI is going to have a transformative impact on the life sciences industry’

Rising stars: Dr Chris Boyle – ‘AI is going to have a transformative impact on the life sciences industry’

Dr Chris Boyle, counsel at Sidley, on the risks and opportunities facing the industry

What do you most enjoy about being a life sciences lawyer?

My passion for science led me to qualify and practice as a veterinary surgeon before I discovered that scientists and clinicians are uniquely placed to make a big impact in law, and I requalified as a life sciences lawyer. The best thing about being a life sciences lawyer is that I can harness my scientific interest and knowledge to serve clients on a far greater scale than I could in veterinary practice, to help them develop the health technologies and services of tomorrow. It is particularly helpful to ‘speak the same language’ when I am advising on matters that require interactions with healthcare professionals and regulators – for example it has proven key in assisting clients with NICE health technology assessments. Continue reading “Rising stars: Dr Chris Boyle – ‘AI is going to have a transformative impact on the life sciences industry’”